Verge Labs partnered with Tenacia Biotechnology to identify new CNS drug targets using Verge’s foundation models and multimodal patient datasets. The collaboration leverages more than 12,000 brain transcriptomes from over 6,500 patients, alongside matched single-cell, proteomic, genomic, and clinical data. The companies will work to prioritize and characterize targets for Tenacia’s CNS programs, marking a broader shift for Verge Labs after moving away from self-developing therapeutics earlier in 2026. Financial terms were not disclosed. The deal underscores how CNS-focused biotechs are increasingly seeking data-rich target discovery engines that can connect molecular signals across modalities—particularly in brain disorders where heterogeneity and access to tissue are recurring challenges. For Tenacia, the agreement is designed to accelerate target decisions, while for Verge it is its first disclosed partnership since the company pivoted its operating model toward platform services.